Caplyta Side Effects
The most common side effects of Caplyta (lumateperone) are sleepiness, dizziness, nausea, and dry mouth, with the medication demonstrating a favorable safety profile including minimal weight gain, metabolic changes, and extrapyramidal symptoms compared to other antipsychotics. 1
Most Common Side Effects (≥5% and twice placebo rate)
According to FDA labeling, the following side effects occur most frequently 1:
- Sleepiness/somnolence
- Dizziness
- Nausea
- Dry mouth
- Fatigue
- Diarrhea
Recent pooled analysis data confirms these findings, with treatment-emergent adverse events occurring in 68.1% of patients on lumateperone versus 45.1% on placebo. Importantly, 96.3% of adverse events were mild to moderate in severity 2.
Serious Side Effects Requiring Immediate Attention
Life-Threatening Risks
Neuroleptic Malignant Syndrome (NMS) - can be fatal. Seek emergency care immediately if you develop 1:
- High fever
- Confusion
- Stiff muscles
- Changes in breathing, heart rate, or blood pressure
- Increased sweating
Stroke risk - increased in elderly patients with dementia-related psychosis (black box warning - Caplyta is NOT approved for this population) 1
Movement Disorders
Tardive dyskinesia - uncontrolled movements of face, tongue, or body parts that may be permanent even after stopping the medication 1. Real-world data shows tremor as the most common extrapyramidal symptom (3.9% vs 0.2% placebo), with mean duration of 11.9 days 2.
Metabolic and Cardiovascular Effects
Metabolic changes requiring monitoring 1:
- High blood sugar/diabetes - check before starting and regularly during treatment
- Warning signs: excessive thirst, frequent urination, extreme hunger, weakness, confusion, fruity breath
- Elevated cholesterol and triglycerides - periodic monitoring needed
- Weight gain - monitor regularly (though notably, only 0.4% experienced ≥7% weight increase versus 1.3% on placebo) 2
Orthostatic hypotension - lightheadedness or fainting when standing up quickly 1
Other Serious Risks
- Low white blood cell count - blood tests needed in first few months 1
- Seizures 1
- Falls - due to sleepiness, dizziness, and orthostatic hypotension leading to fractures or injuries 1
- Difficulty swallowing - can cause aspiration 1
- Temperature regulation problems - feeling too warm 1
- Fertility problems in both males and females 1
Discontinuation Rates
Treatment discontinuation due to adverse events occurred in 8.7% of patients on lumateperone versus only 0.8% on placebo 2. This higher discontinuation rate is a clinically important consideration despite the generally favorable tolerability profile.
Time Course of Adverse Events
Most adverse events occur within the first 10 days to 1 month after starting lumateperone, with median onset at 9 days 3.
Special Populations Warning
Increased suicidal thoughts and actions - particularly in children, adolescents, and young adults, especially within the first few months or when dose changes 1. Watch for new or worsening depression, anxiety, agitation, panic attacks, insomnia, irritability, aggression, suicidal thoughts, or unusual behavior changes.
Favorable Safety Profile Compared to Other Antipsychotics
Caplyta demonstrates placebo-level rates of 2, 4:
- Weight gain (0.4% with ≥7% increase)
- Metabolic disruption (minimal changes in cardiometabolic parameters)
- Prolactin elevation (minimal changes)
- Extrapyramidal symptoms excluding tremor
This positions lumateperone as having one of the most favorable metabolic and movement disorder profiles among atypical antipsychotics, which is particularly relevant for long-term morbidity and quality of life outcomes.